Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Hum Immunol. 2017 Mar 4;78(4):342–349. doi: 10.1016/j.humimm.2017.03.002

Figure 5.

Figure 5

(A). The levels of DcfDNA in patient who developed acute rejection compared to that from stable or BOS positive patients. B. The time course of the level of donor cfDNA in stable patient who developed BAL culture positive infection (B).